There has been a strong uptick in IPO activity this year compared to 2023 when the market witnessed a slowdown. In the
Everything you need to know about OS Therapies’ upcoming IPO
Categories
Health Care
MEDS Earnings: Highlights of Trxade Health’s Q1 2024 financial results
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported financial results for the first quarter of 2024. The company
Alumis looks to raise $300 million in IPO. Here’s what you need to know
Technology and healthcare companies are continuing to dominate the IPO market, which is witnessing a significant increase in activity compared to 2023.
WBA Earnings Preview: Will Walgreens’ Q3 report bring cheer to investors?
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has been facing challenges due to higher operating costs, rising competition, and an unfavorable retail environment.
Tempus AI gears up for IPO. Here’s everything you need to know
The IPO market witnessed stronger activity so far this year compared to the corresponding period last year, with a marked increase in
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by partnering with
Key metrics from Medtronic’s (MDT) Q4 2024 earnings results
Medtronic plc (NYSE: MDT) reported fourth quarter 2024 earnings results today. Worldwide revenue was $8.6 billion, up 0.5% on a reported basis
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform that digitalizes the retail pharmacy experience. The company has a
Earnings Summary: Organon reports financial results for Q1 2024
Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024. First-quarter revenue
Cigna Group (CI) reports double-digit revenue growth for Q1; guides FY24
The Cigna Group (NYSE: CI), a healthcare company focused on medical insurance and related services, Thursday reported a sharp increase in revenues for
Infographic: A snapshot of Moderna’s (MRNA) Q1 2024 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company's revenues declined sharply. Q1
Key takeaways from Pfizer’s (PFE) Q1 2024 earnings report
Shares of Pfizer Inc. (NYSE: PFE) gained over 5% on Wednesday following the company’s announcement of its first quarter 2024 earnings results.
CVS Health Q1 adj. earnings drop despite revenue growth; guides FY24
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) announced first-quarter 2024 results, reporting higher revenues and a decrease in adjusted earnings. March-quarter adjusted
Pfizer (PFE) Q1 2024 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported first quarter 2024 earnings results today. Revenues decreased 20% year-over-year to $14.8 billion. Reported net income declined
Key highlights from Eli Lilly’s (LLY) Q1 2024 earnings results
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the
Highlights of AbbVie’s Q1 2024 financial results
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest
Key highlights from Bristol Myers Squibb’s (BMY) Q1 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today. Total revenues increased 5% year-over-year to $11.9 billion. When adjusted
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline
Earnings: Trxade Health (MEDS) reports lower revenues for fiscal 2023
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decline in revenues for fiscal 2023. The company’s full-year
ISRG Earnings: Intuitive Surgical reports higher Q1 revenue and profit
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) announced operating results for the first quarter of 2024, reporting higher revenues and adjusted